PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11079258

Lipid and lipoprotein patterns in type 2 non-obese diabetic patients. Do Lp(a) levels decrease with improved glycemic control in these patients?

H Alagözlü·F Gültekin·F Candan
View original source ↗Export metadata ↓

Abstract

BACKGROUND AND AIM: In this study, we investigated the levels of apolipopotein-AI (apo-AI), apolipoprotein (apo-B), triglyceride (TG), high-density-lipoprotein-cholesterol (HDL-C), low-density-lipoprotein-cholesterol (LDL-C), total cholesterol, lipoprotein(a) in a group of non-obese, type 2 diabetes mellitus patients with different types of treatment and a control group of non-obese, non-diabetic subjects. METHODS AND RESULTS: Patients were divided into three groups according to their treatment types: insulin, sulphonylurea and untreated groups. All groups were similar in sex, weights, known duration of diabetes and habits. Each group consisted of 30 subjects. There were no differences in apo-AI, apo-B and TG levels (p > 0.05), whereas HDL-C levels in the untreated group were significantly lower than those of the other groups (p < 0.05). Lp(a) levels in the untreated group were higher than in the other (p < 0.05). CONCLUSIONS: Gaining metabolic control in diabetes mellitus is crucial in pulling back lipid, lipoprotein and apolipoprotein levels to a desired level and in attenuating CAD (coronary artery disease) risk factors, and also in preventing CAD. Lp(a) levels in particular are decreased by insulin or sulfonylurea in non-obese patients with type 2 diabetes mellitus.

Explore related subjects

Apolipoprotein A-IApolipoproteins BBlood GlucoseCholesterolCholesterol, HDLCholesterol, LDLDiabetes Mellitus, Type 2FemaleGliclazideGlycated HemoglobinHumansInsulinLipidsLipoprotein(a)LipoproteinsMaleReference ValuesSulfonylurea CompoundsTriglyceridesComparative StudyJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Alagözlü, F Gültekin, F Candan. 2000. Lipid and lipoprotein patterns in type 2 non-obese diabetic patients. Do Lp(a) levels decrease with improved glycemic control in these patients?. https://pubmed.ncbi.nlm.nih.gov/11079258/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Transcription factor NF-Y regulates differentiation of CaCo-2 cells.

The CaCo-2 cell line is used to study the molecular mechanisms underlying differentiation of intestinal epithelial cells. These cells undergo a gradual differentiation process that is growth-related and depends on cellular density. CaCo-2 cells acquire a morphological polarity and express such markers of mature enterocytes as sucrase-isomaltase, apolipoproteins, alkaline phosphatase, and H-ferritin. Because the NF-Y transcription factor is required for H-ferritin gene expression, we investigated whether it is involved in the expression of the other CaCo-2 differentiation markers. We observed that subunit NF-YA increases during CaCo-2 differentiation and that the constitutive expression of NF-YA, obtained in stably transfected CaCo-2 cells, results in the expression of differentiation markers. In fact, sucrase-isomaltase, apolipoprotein A1, and H-ferritin were constitutively expressed in NF-YA-transfected cells and their levels did not increase during prolonged culture, while these markers were not expressed in mock-transfected CaCo-2 cells or transfected with an inactive NF-YA expression vector until the onset of differentiation.

Apolipoprotein A-I↗
PubMed2002

Evidence that phospholipids play a key role in pre-beta apoA-I formation and high-density lipoprotein remodeling.

The initial plasma acceptor of unesterified cholesterol and phospholipids from peripheral cells has been identified as pre-beta migrating, lipid-free, or lipid-poor apolipoprotein (apo) A-I (pre-beta apoA-I). Pre-beta apoA-I is formed when plasma factors, such as cholesteryl ester transfer protein (CETP), remodel high-density lipoproteins (HDL). The aim of this study is to determine how phospholipids influence pre-beta apoA-I formation during the CETP-mediated remodeling of HDL. Reconstituted HDL (rHDL) containing either 1-palmitoyl-2-oleoyl phosphatidylcholine (POPC), 1-palmitoyl-2-linoleoyl phosphatidylcholine (PLPC), 1-palmitoyl-2-arachidonyl phosphatidylcholine (PAPC), or 1-palmitoyl-2-docosahexanoyl phosphatidylcholine (PDPC) as the only phospholipid were prepared. The rHDL were comparable in size and core lipid/protein molar ratio and contained only cholesteryl esters in their core and apoA-I as the sole apolipoprotein. The (POPC)rHDL, (PLPC)rHDL, (PAPC)rHDL, and (PDPC)rHDL were respectively incubated for 0-24 h with CETP and microemulsions containing triolein and either POPC, PLPC, PAPC, or PDPC. The rate at which the rHDL were depleted of core lipids and remodeled to small particles varied widely with (POPC)rHDL < (PLPC)rHDL < (PDPC)rHDL approximately (PAPC)rHDL. Pre-beta apoA-I was not formed in the (POPC)rHDL incubations. Pre-beta apoA-I was apparent by 24 h in the (PLPC)rHDL incubations and by 12 h in the (PAPC)rHDL and (PDPC)rHDL incubations. The enhanced formation of pre-beta apoA-I in the (PAPC)rHDL and (PDPC)rHDL incubations reflected the increased core lipid depletion of the particles combined with the destabilization and progressive exclusion of apoA-I from the particle surface. In conclusion, these results show that phospholipids play a key role in the CETP-mediated remodeling of rHDL and pre-beta apoA-I formation.

Apolipoprotein A-I↗
PubMed2002

How the lipid-free structure of the N-terminal truncated human apoA-I converts to the lipid-bound form: new insights from NMR and X-ray structural comparison.

The X-ray structure of the N-terminal truncated human apoA-I [Borhani et al., Proc. Natl. Acad. Sci. USA 94 (1997) 12291] and the NMR structure of intact human apoA-I [Okon et al., FEBS Lett. 517 (2002) 139] found similar repeating helices. The crystal structure is a twisted circular four-helix bundle, consisting of four molecules of apoA-I(44-243), where four copies of the lecithin:cholesterol acyltransferase (LCAT)-activating domains are located outside the ring structure, while the aromatic-rich strong lipid-binding domains are inside. This architecture suggests a lipid-binding mechanism that lipids directly enter the hole of the crystal structure. Indeed, four copies of Trp50 and Trp72 are exposed and oriented toward the center of the ring, initiating lipid binding. This is followed by the inside-out rotations of the terminal helices to make a belt with all the hydrophobic faces of the helices facing inward. Such lipid-binding induced rotations have an impact on the conformation of the lipid-free form. Indeed, the structure of residues 78-81 changes from helical (free) to disordered (bound) while the structure of residues 221-227 changes from extended to helical.

Apolipoprotein A-I↗